All In Biotech

Drug Trial Radar · NCT03740958

Argatroban Plus R-tPA for Acute Ischemic Stroke

Argatroban Plus R-tPA for Acute Ischemic Stroke: a Prospective, Random, Open Label, Blinded Assessment of Outcome Multi-center Study

Last checked: Nov 20, 2026Latest source record: Feb 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 808 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

808

Actual

Start

Dec 21, 2018

Primary completion

Jan 30, 2022

Study completion Jan 30, 2022

Sponsor

Lead sponsor
General Hospital of Shenyang Military RegionAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute ischemic stroke (AIS) is the most common type of stroke, which has high rate of morbidity, mortality and disability. A large number of studies have confirmed that the thrombolytic therapy can effectively open blood vessels and improve the functional prognosis of acute ischemic stroke. Therefore, all guidelines recommend intravenous thrombolysis as the first treatment of ischemic stroke patients within 4.5 hours of onset. However, about 1/3 patients receiving thrombolysis will have good prognosis, while a large number of patients will still be disabled and even dead. How to improve the neurological prognosis of thrombolytic patients has been a hot topic in the world. Recent studies have found that the combined application of argatroban and rt-PA in the treatment of AIS might improve the clinical prognosis and not significantly increase bleeding. Some studies have reported that the combined application of argatroban and rt-PA could improve the blood vessel opening rate, and prevent re-occlusion after opening. Based on the discussion, the present study is designed to explore the efficacy and safety of argatroban plus rt-PA in the treatment of AIS.

Conditions

  • Stroke

Interventions

  • rt-PADrug

    Intravenous throbolysis with 0.9mg/kg rtPA

  • ArgatrobanDrug

    100 ug/kg bolus over 3 to 5 minutes was administered intravenously, followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of mRS (0-1)Time frame: 90±7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • General Hospital of ShenYang Military Region

    Shenyang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.